The SAE Media Group's 3rd Annual Depression & Anxiety Conference will bring together the key industry leaders to discuss the current and future opportunities within psychopharmacotherapy.
This is a must-attend event for all those involved in addressing the growing challenges of diagnosing and treating the spectrum of distinct disorders.
This two day intensive forum will help you learn more about: |  |
- Drug development and new compounds: examine the emerging developments from the psychopharmaceutical drug pipelines and investigate the challenges that must be considered by the psychopharmacological community
- Avoiding trial failure and improving study design: discover novel approaches specific to designing clinical studies for patients with mood disorders
- Psychogenomics: hear about how genetics could provide the key to producing a truly individualised therapy system, and how the latest discoveries could help salvage previously doomed drug candidates
- Translational issues in mood disorders: using translational methods to overcome traditional obstacles while developing new treatments for mood disorders
- New targets and Biomarkers in lead discovery: identify new targets and improve biomarker selections to predict the effectiveness and safety of drugs for the treatment of depression
The conference features an excellent opportunity to hear from an international panel of experts, including:
- Dr Lee E. Schechter, Therapeutic Area Head, Director Depression & Anxiety Research, Neuroscience Discovery, Wyeth
- Dr Tanya Ramey, Clinical Lead, Neurosciences, Pfizer
- Dr Pim Drinkenburg, Research Fellow, Head Biomonitoring Centre of Expertise Europe, Johnson & Johnson
- Dr Zhengming Chen, Senior Director, Chemistry, DOV Pharmaceuticals
- Dr Vincent F. Simmon, President & CEO, Xytis Pharmaceuticals
- Dr Dinah Weissman, CEO, Biocortech
- Dr Miguel Medina, Drug Discovery Director, Neuropharma
- Dr Jill Rasmussen, Director, Psynapse
- Prof Tonmoy Sharma, Director, Clinical Neuroscience Research Centre
- Dr Andrew Harkin, Director, Neuropsychopharmacology Research, Trinity College Institute if Neuroscience, Trinity College, Dublin
- Professor Charles Marsden, Institute of Neuroscience, School of Biomedical Sciences, University of Nottingham Medical School
Who should attend Depression & Anxiety 2007?
You should attend this conference if you are an Executive, Director or scientist working in the pharmaceutical or biotech industries within:
Behavioural NeuroscienceCNSBiomonitoringClinical DevelopmentScientific ServicesResearch & DevelopmentPsychopharmacology ResearchClinical PsychologyClinical PharmacodynamicsMarketingPortfolio ManagementMarketingProject management